Silent murder kills at dawn;El «asesino silencioso» actúa temprano

Nefrologia

Volumn 23, Issue 5, 2003, Pages 377-380

  Fernandez Giraldez E ^a  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY FAILURE; EDITORIAL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; MORTALITY; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM;

HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHORUS METABOLISM DISORDERS;

EID: 1542756295     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (15)

1. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink N, Martín A, Klag MJ: Traditional cardiovascular disease risk factors in diálisis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 13: 1918-1927, 2002.
2. Registre de malalts renals de Catalunya: Informe estadístic 2001.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31 (4): 607-617, 1998.
4. Levin NW, Hoenich NA: Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens 10 (5): 563-568, 2001.
5. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernández E: Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney int (Supl. 85): 111-114, 2003.
6. Taal MW, Roe S, Masud T, Green D, Porter©, Cassidy MJD: Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63: 1116-1120; 2003-06-30.
7. Von der Recke P, Hansen MA, Hassager©: The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106: 273-278, 1999.
8. Raggi P, Boulay A, Chasan-Tabar S, Amin NS, Dillon MA, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. J Am Coll Cardiol 39: 695-701, 2002.
9. Bucay N, Saroray I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice developed early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268, 1998.
10. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giacelli CM: Phosphate regulation of vascular smooth muscle cell calcificatio. Circ Res 87: 10-17, 2000.
11. Amann K, Törning J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia.
12. Amann K, Ritz E, Wiest G y cols.: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4: 1814-1819, 1994.
13. Block G, Port FK: Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disase. Sem Dial 16: 140-147, 2003.
14. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287: 1548-1555, 2002.
15. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney Int 47: 186-192, 1995.